Zoetis Inc. $ZTS Stock Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its position in Zoetis Inc. (NYSE:ZTS) by 10.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 918,176 shares of the company’s stock after selling 101,876 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Zoetis were worth $64,116,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZTS. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis in the 1st quarter worth approximately $28,000. Root Financial Partners LLC increased its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Wellington Grp LLC grew its stake in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in Zoetis in the 1st quarter valued at approximately $38,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis in the second quarter valued at about $25,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. The Goldman Sachs Group initiated coverage on Zoetis in a research report on Friday, October 16th. They set a “neutral” rating and a $74.00 price objective for the company. Zacks Research upgraded shares of Zoetis from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Morgan Stanley lowered their target price on Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Thursday, October 29th. TD Cowen lowered their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Finally, William Blair downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $93.79.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $83.19 on Wednesday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The business’s 50 day moving average is $75.27 and its two-hundred day moving average is $93.22. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $132.49. The company has a market cap of $34.38 billion, a P/E ratio of 13.71, a P/E/G ratio of 1.23 and a beta of 0.67.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. Zoetis’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.